| Literature DB >> 26151079 |
Scott A Shaw1, Balu Balasubramanian1, Samuel Bonacorsi1, Janet Caceres Cortes1, Kevin Cao1, Bang-Chi Chen1, Jun Dai1, Carl Decicco1, Animesh Goswami1, Zhiwei Guo1, Ronald Hanson1, W Griffith Humphreys1, Patrick Y S Lam1, Wenying Li1, Arvind Mathur1, Brad D Maxwell1, Quentin Michaudel2, Li Peng1, Andrew Pudzianowski1, Feng Qiu1, Shun Su2, Dawn Sun1, Adrienne A Tymiak1, Benjamin P Vokits1, Bei Wang1, Ruth Wexler1, Dauh-Rurng Wu1, Yingru Zhang1, Rulin Zhao1, Phil S Baran2.
Abstract
Clopidogrel is a prodrug anticoagulant with active metabolites that irreversibly inhibit the platelet surface GPCR P2Y12 and thus inhibit platelet activation. However, gaining an understanding of patient response has been limited due to imprecise understanding of metabolite activity and stereochemistry, and a lack of acceptable analytes for quantifying in vivo metabolite formation. Methods for the production of all bioactive metabolites of clopidogrel, their stereochemical assignment, and the development of stable analytes via three conceptually orthogonal routes are disclosed.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26151079 DOI: 10.1021/acs.joc.5b00632
Source DB: PubMed Journal: J Org Chem ISSN: 0022-3263 Impact factor: 4.354